vs

Side-by-side financial comparison of KINGSTONE COMPANIES, INC. (KINS) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

KINGSTONE COMPANIES, INC. is the larger business by last-quarter revenue ($56.4M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). KINGSTONE COMPANIES, INC. runs the higher net margin — 26.2% vs -304.2%, a 330.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 34.0%). KINGSTONE COMPANIES, INC. produced more free cash flow last quarter ($73.1M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 25.6%).

Kingstone Companies, Inc., headquartered in Kingston, New York, provides property and casualty insurance products through its subsidiary, Kingstone Insurance Company. It places contracts with the third-party licensed premium finance company through its subsidiary Payments, Inc., a NYS licensed Insurance Premium Finance Company. Kingstone Insurance Company was ranked #1 of the 81 insurers rated by the Professional Insurance Agents Association in its 2010 Company Performance Survey. The company...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

KINS vs RXRX — Head-to-Head

Bigger by revenue
KINS
KINS
1.6× larger
KINS
$56.4M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+647.7% gap
RXRX
681.7%
34.0%
KINS
Higher net margin
KINS
KINS
330.4% more per $
KINS
26.2%
-304.2%
RXRX
More free cash flow
KINS
KINS
$120.4M more FCF
KINS
$73.1M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
25.6%
KINS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KINS
KINS
RXRX
RXRX
Revenue
$56.4M
$35.5M
Net Profit
$14.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
32.7%
-304.8%
Net Margin
26.2%
-304.2%
Revenue YoY
34.0%
681.7%
Net Profit YoY
171.4%
39.6%
EPS (diluted)
$1.09
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KINS
KINS
RXRX
RXRX
Q4 25
$56.4M
$35.5M
Q3 25
$55.7M
$5.2M
Q2 25
$52.3M
$19.2M
Q1 25
$50.5M
$14.7M
Q4 24
$42.1M
$4.5M
Q3 24
$40.8M
$26.1M
Q2 24
$36.5M
$14.4M
Q1 24
$35.8M
$13.8M
Net Profit
KINS
KINS
RXRX
RXRX
Q4 25
$14.8M
$-108.1M
Q3 25
$10.9M
$-162.3M
Q2 25
$11.3M
$-171.9M
Q1 25
$3.9M
$-202.5M
Q4 24
$5.4M
$-178.9M
Q3 24
$7.0M
$-95.8M
Q2 24
$4.5M
$-97.5M
Q1 24
$1.4M
$-91.4M
Gross Margin
KINS
KINS
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
KINS
KINS
RXRX
RXRX
Q4 25
32.7%
-304.8%
Q3 25
24.6%
-3327.6%
Q2 25
27.1%
-916.8%
Q1 25
9.3%
-1297.9%
Q4 24
15.9%
-4042.4%
Q3 24
22.3%
-377.1%
Q2 24
15.7%
-697.4%
Q1 24
5.0%
-698.4%
Net Margin
KINS
KINS
RXRX
RXRX
Q4 25
26.2%
-304.2%
Q3 25
19.5%
-3135.3%
Q2 25
21.5%
-894.2%
Q1 25
7.7%
-1373.3%
Q4 24
12.9%
-3935.5%
Q3 24
17.1%
-367.5%
Q2 24
12.4%
-676.6%
Q1 24
4.0%
-662.4%
EPS (diluted)
KINS
KINS
RXRX
RXRX
Q4 25
$1.09
$-0.17
Q3 25
$0.74
$-0.36
Q2 25
$0.78
$-0.41
Q1 25
$0.27
$-0.50
Q4 24
$0.44
$-0.56
Q3 24
$0.55
$-0.34
Q2 24
$0.37
$-0.40
Q1 24
$0.12
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KINS
KINS
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$4.4M
$9.6M
Stockholders' EquityBook value
$122.7M
$1.1B
Total Assets
$453.4M
$1.5B
Debt / EquityLower = less leverage
0.04×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KINS
KINS
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
KINS
KINS
RXRX
RXRX
Q4 25
$4.4M
$9.6M
Q3 25
$4.8M
$11.9M
Q2 25
$5.1M
$14.2M
Q1 25
$5.4M
$16.4M
Q4 24
$11.2M
$19.0M
Q3 24
$17.3M
$20.5M
Q2 24
$25.3M
$22.9M
Q1 24
$25.3M
Stockholders' Equity
KINS
KINS
RXRX
RXRX
Q4 25
$122.7M
$1.1B
Q3 25
$107.7M
$1.0B
Q2 25
$94.9M
$919.1M
Q1 25
$82.2M
$933.9M
Q4 24
$66.7M
$1.0B
Q3 24
$59.7M
$524.6M
Q2 24
$40.8M
$584.4M
Q1 24
$35.7M
$401.2M
Total Assets
KINS
KINS
RXRX
RXRX
Q4 25
$453.4M
$1.5B
Q3 25
$428.6M
$1.4B
Q2 25
$393.4M
$1.3B
Q1 25
$385.4M
$1.3B
Q4 24
$374.9M
$1.4B
Q3 24
$347.0M
$726.5M
Q2 24
$319.8M
$775.9M
Q1 24
$318.3M
$557.8M
Debt / Equity
KINS
KINS
RXRX
RXRX
Q4 25
0.04×
0.01×
Q3 25
0.04×
0.01×
Q2 25
0.05×
0.02×
Q1 25
0.07×
0.02×
Q4 24
0.17×
0.02×
Q3 24
0.29×
0.04×
Q2 24
0.62×
0.04×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KINS
KINS
RXRX
RXRX
Operating Cash FlowLast quarter
$75.9M
$-46.1M
Free Cash FlowOCF − Capex
$73.1M
$-47.3M
FCF MarginFCF / Revenue
129.5%
-133.1%
Capex IntensityCapex / Revenue
5.0%
3.5%
Cash ConversionOCF / Net Profit
5.14×
TTM Free Cash FlowTrailing 4 quarters
$124.0M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KINS
KINS
RXRX
RXRX
Q4 25
$75.9M
$-46.1M
Q3 25
$25.9M
$-117.4M
Q2 25
$9.3M
$-76.4M
Q1 25
$17.9M
$-132.0M
Q4 24
$57.9M
$-115.4M
Q3 24
$21.7M
$-59.2M
Q2 24
$7.1M
$-82.2M
Q1 24
$6.1M
$-102.3M
Free Cash Flow
KINS
KINS
RXRX
RXRX
Q4 25
$73.1M
$-47.3M
Q3 25
$25.3M
$-117.6M
Q2 25
$8.7M
$-79.6M
Q1 25
$17.0M
$-133.8M
Q4 24
$55.6M
$-116.7M
Q3 24
$21.0M
$-63.8M
Q2 24
$6.6M
$-83.4M
Q1 24
$5.6M
$-109.0M
FCF Margin
KINS
KINS
RXRX
RXRX
Q4 25
129.5%
-133.1%
Q3 25
45.4%
-2272.5%
Q2 25
16.6%
-413.9%
Q1 25
33.7%
-907.4%
Q4 24
132.1%
-2567.7%
Q3 24
51.6%
-244.6%
Q2 24
18.1%
-578.5%
Q1 24
15.5%
-789.9%
Capex Intensity
KINS
KINS
RXRX
RXRX
Q4 25
5.0%
3.5%
Q3 25
1.2%
4.7%
Q2 25
1.1%
16.4%
Q1 25
1.7%
12.4%
Q4 24
5.6%
28.6%
Q3 24
1.7%
17.5%
Q2 24
1.4%
8.2%
Q1 24
1.5%
48.2%
Cash Conversion
KINS
KINS
RXRX
RXRX
Q4 25
5.14×
Q3 25
2.38×
Q2 25
0.82×
Q1 25
4.60×
Q4 24
10.65×
Q3 24
3.12×
Q2 24
1.58×
Q1 24
4.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons